Form 4: Vir Biotechnology SVP Acquires Shares and Options, Sells Shares for Tax Obligations
SEC Form 4
Brent Sabatini, SVP and Chief Accounting Officer of Vir Biotechnology, acquired shares and options while selling shares to cover tax obligations related to vesting restricted stock units.
Summary
- Brent Sabatini, SVP, Chief Accounting Officer of Vir Biotechnology, filed a Form 4.
- On February 22, 2025, Sabatini acquired 20,000 shares of common stock and 40,000 stock options at a price of $0.
- On February 24, 2025, Sabatini sold 1,562 shares of common stock at $9.4534 per share.
- The sale was to cover the issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
- Following these transactions, Sabatini beneficially owns 46,627 shares of common stock and 40,000 stock options.
Sentiment
Score: 6
Explanation: Neutral sentiment as the transactions are a mix of acquisitions and sales for tax purposes, indicating standard executive compensation practices.
Positives
- Acquisition of 40,000 stock options by Sabatini indicates confidence in the company's future performance.
Negatives
- The sale of 1,562 shares, while for tax obligations, could be perceived negatively by some investors.
Industry Context
Insider transactions are closely monitored in the biotechnology industry to gauge executive sentiment and potential future performance of the company.
Comparison to Industry Standards
- Comparing Sabatini's transactions to similar filings by executives at companies like Gilead Sciences or Regeneron Pharmaceuticals could provide context on the scale and nature of these transactions.
- Stock option grants are a common form of executive compensation in the biotech industry, aligning management's interests with those of shareholders.
- Sales of shares to cover tax obligations are also typical, especially after the vesting of restricted stock units.
Stakeholder Impact
- The transactions could have a minor impact on shareholder sentiment, depending on how they interpret the insider activity.
Key Dates
| Date | Description |
|---|---|
| 02/22/2025 | Acquisition of 20,000 common stock shares and 40,000 stock options. |
| 02/24/2025 | Sale of 1,562 common stock shares to cover tax obligations. |
| 02/25/2025 | Date of signature for the Form 4 filing. |
| 02/22/2026 | 25% of the acquired stock options vest and become exercisable. |
| 02/21/2035 | Expiration date of the acquired stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.